Compare Mercadolibre Inc (MELI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Neurocrine Biosciences Inc — how do they compare? Mercadolibre Inc trades at $1,891.71 (market cap $94.13B), while Neurocrine Biosciences Inc trades at $142.39 (market cap $14.36B). The key difference: Mercadolibre Inc is far larger — about 6.6× Neurocrine Biosciences Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 117 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MELI | NBIX | |
|---|---|---|
Market Cap | $94.13B | $14.36B |
Volume | 273,781 | 1,237,180 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.36K | $185.50 |
52-Week Low | $1.55K | $123.10 |
Typical Hold Time | 117 Days | 23 Days |
Enterprise Value | $101.77B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,873.57, up 0.04% on the day, with a bullish technical signal from moving averages and strong support near $1,813. The company reported $28.89B revenue in 2025, though net income margin dipped to 6.91%, and recent earnings show mixed results with a beat in Q2 2026 but misses in prior quarters. Analyst consensus is strongly positive with a $2,170 price target, and cash flow from operations surged to $12.12B in 2025, underscoring robust financial health.
Outlook remains favorable due to dominant e-commerce and fintech positioning in Latin America, with revenue projected to hit $35.2B in 2026. Risks include profit margin pressures and macroeconomic volatility in key markets like Argentina. Institutional sentiment is bullish, with 73% of analysts rating it Buy, supporting potential upside near all-time highs.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
